Trusted Resource for Clinical Trials, Protocols & Progress
Surveillance of Rare Adverse Events Post-Vaccination How to Monitor Rare Adverse Events After Vaccination Why Rare-Event Surveillance Matters and What Regulators Expect Licensure is not the finish line for safety; it is the start of population-scale learning. Even very large pre-licensure trials are underpowered for events with true incidences of 1–10 per million doses (e.g.,…
Read More “Surveillance of Rare Adverse Events Post-Vaccination” »
Regulatory Requirements for Immunogenicity Reporting Regulatory Requirements for Reporting Immunogenicity Data What Regulators Expect Across Protocol, SAP, and CSR Immunogenicity readouts drive dose and schedule selection, immunobridging, and—frequently—support accelerated or conditional approvals. Regulators expect to see a coherent story that links what you measure to why it matters and how it was analyzed. In the…
Read More “Regulatory Requirements for Immunogenicity Reporting” »
Comparing Humoral vs Cellular Immunity in Vaccines Humoral vs Cellular Immunity in Vaccine Trials: What to Measure, How to Compare, and When It Matters Humoral and Cellular Immunity—Different Jobs, Shared Goal Vaccine programs routinely track two arms of the adaptive immune system. Humoral immunity is quantified by binding antibody concentrations (e.g., ELISA IgG geometric mean…
Read More “Comparing Humoral vs Cellular Immunity in Vaccines” »
